Evidence map›Paper›PMID 40584156›Full record

ArticleJBMR plus2025

Uncemented hip arthroplasty and denosumab: increased postoperative dipeptide concentrations and identification of potential new bone turnover biomarkers.

Kim Kultima, Saman Hosseini Ashtiani, Ida Erngren, Payam Emami Khoonsari, Henrik Carlsson, Stephanie Herman, Eva Freyhult, Hans Mallmin, Nils P Hailer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JBMR plus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kim KultimaDepartment of Medical Sciences, Clinical Chemistry, Uppsala University, 751 85 Uppsala, Sweden.ORCID https://orcid.org/0000-0002-0680-1410
Saman Hosseini AshtianiDepartment of Medical Sciences, Clinical Chemistry, Uppsala University, 751 85 Uppsala, Sweden.
Ida ErngrenDepartment of Medical Sciences, Clinical Chemistry, Uppsala University, 751 85 Uppsala, Sweden.
Payam Emami KhoonsariDepartment of Medical Sciences, Clinical Chemistry, Uppsala University, 751 85 Uppsala, Sweden.
Henrik CarlssonDepartment of Medical Sciences, Clinical Chemistry, Uppsala University, 751 85 Uppsala, Sweden.
Stephanie HermanDepartment of Medical Sciences, Clinical Chemistry, Uppsala University, 751 85 Uppsala, Sweden.
Eva FreyhultDepartment of Cell and Molecular Biology, Uppsala University, 751 24 Uppsala, Sweden.
Hans MallminDepartment of Surgical Sciences/Orthopaedics, Uppsala University, 751 85 Uppsala, Sweden.
Nils P HailerDepartment of Surgical Sciences/Orthopaedics, Uppsala University, 751 85 Uppsala, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Denosumab is a potent antagonist of RANKL and is widely used to treat severe postmenopausal osteoporosis. Using high-resolution mass spectrometry (HRMS), we aimed to identify molecular mediators associated with the rapid reactivation of osteoclasts following discontinuation of denosumab. In a previously reported randomized controlled trial, 64 patients undergoing uncemented total hip arthroplasty were randomized to receive 2 doses of 60 mg denosumab or placebo, administered 1-3 d and 6 mo postoperatively. Serum samples were analyzed using untargeted HRMS coupled with liquid chromatography, and bone turnover markers were assessed. Data were evaluated using linear mixed-effects models and machine learning techniques. After surgery, 83 metabolite features showed significant concentration changes (

Indexed as

bone turnover biomarkersdenosumabdipeptideshigh-resolution mass spectrometrymetabolomicsosteoclast activityperiprosthetic bone lossrebound bone losstotal hip arthroplasty

Identifiers

PMID40584156
PMCPMC12202150

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.